SCHEMBL23294791

SCHEMBL23294791

C[C@@H]1CN(c2cccc3nc4ccc(-c5ccc(N6CCC(N(C)C)CC6)c(Cl)c5)cn4c23)C[C@H](C)N1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 2/20 0.34
▸ HTR6 P50406 2/20 0.34
▸ MET P08581 1/20 0.34
▸ PDE3B Q13370 1/20 0.34
▸ PDE3A Q14432 1/20 0.34
▸ PIK3CA P42336 3/20 0.33
▸ PDCD1 Q15116 1/20 0.33
▸ CD274 Q9NZQ7 1/20 0.33
▸ WEE1 P30291 2/20 0.33
▸ KCNH2 Q12809 3/20 0.32
▸ EIF4E P06730 1/20 0.32
▸ MKNK1 Q9BUB5 1/20 0.32
▸ MKNK2 Q9HBH9 1/20 0.32
▸ JAK1 P23458 1/20 0.32
▸ JAK3 P52333 1/20 0.32
▸ EGFR P00533 3/20 0.32
▸ PTPN11 Q06124 1/20 0.32
▸ ATM Q13315 2/20 0.31
▸ ATR Q13535 2/20 0.31
▸ MTOR P42345 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23294875 0.92 MAOB (0.38) MAOBHTR6METPDE3BPDE3A
SCHEMBL23294825 0.91 PIK3CD (0.35) METPDE3BPDE3APIK3CAPDCD1
SCHEMBL30116734 0.91 PIK3CD (0.35) METPDE3BPDE3APIK3CAPDCD1
SCHEMBL23294787 0.90 HSD11B1 (0.35) METPDE3BPDE3APIK3CAPDCD1
SCHEMBL23294811 0.88 MET (0.36) MAOBHTR6METPDE3BPDE3A
SCHEMBL23294917 0.82 PIK3CA (0.36) MAOBHTR6METPDE3BPDE3A
SCHEMBL23294788 0.82 PIK3CD (0.37) MAOBHTR6METPDE3BPDE3A
SCHEMBL23294818 0.82 PIK3CA (0.37) MAOBHTR6METPDE3BPDE3A
SCHEMBL23294810 0.80 ASIC3 (0.41) PDE3BPDE3AKCNH2MTOR
SCHEMBL23294848 0.80 PIK3CA (0.36) METPDE3BPDE3APIK3CAPDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2021-05-06 — — US claimed
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof Impact Therapeutics (Shanghai), Inc (CN) 2023-01-10 — — US disclosed
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof IMPACT THERAPEUTICS, INC. (CN) 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210128535-A1 Substituted Fused Heteroaromatic Tricyclic Compounds as Kinase Inhibitors and The Use Thereof CHEK2, CHEK1, ATM MAOB 2118/4885HTR6 3107/4885MET 2037/4885
US-11547703-B2 Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof CHEK2, CHEK1, ATM MAOB 2118/4885HTR6 3107/4885MET 2037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback